In the ongoing study, Biktarvy was found to be statistically non-inferior to a regimen of abacavir/dolutegravir/lamivudine (600/50/300mg, ABC/DTG/3TC) through 96 weeks of therapy. The data will be presented
The post Gilead Sciences’ Biktarvy shows high efficacy in HIV-1 study appeared first on Pharma Business review.
Original Article: Gilead Sciences’ Biktarvy shows high efficacy in HIV-1 study